Table 1.
Genotypes and corresponding phenotypes in individuals with ultra-rare POU3F2 variants identified by exome/genome sequencing
ID 1.1 | ID 1.2 | ID 2 | ID 3 | ID 412 | ID 5.1a | ID 5.2a | ID 6 | ID 7b | ID 8 | ID 9 | ID 10 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Genotype | ||||||||||||
Inheritance | maternal | unknown | de novo | de novo | de novo | paternal | unknown | de novo | de novo | de novo | unknown | de novo |
Zygosity | het | het | het | het | het | het | het | het | het | het | het | het |
Coding position | c.135C>A | c.135C>A | c.914A>G | c.41C>T | c.812A>T | c.664C>T | c.664C>T | c.929G>C | c.1249_1252del | c.1064G>T | c.1325T>C | c.1212C>A |
Protein position | p.Tyr45∗ | p.Tyr45∗ | p.Gln305Arg | p.Ser14Phe | p.Glu271Val | p.Pro222Ser | p.Pro222Ser | p.Arg310Thr | p.Gly417Leufs∗71 | p.Arg355Leu | p.Val442Ala | p.Asn404Lys |
MAF (gnomAD) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 9.78 × 10−6 | 0 |
CADD PHRED | 34.0 | 34.0 | 28.6 | 22.9 | 31.0 | 20.0 | 20.0 | 29.7 | 33 | 32.0 | 28.8 | 29.6 |
Affecting POU-protein domainsc | yes | yes | yes | no | yes | no | no | yes | no | yes | no | yes |
Phenotype | ||||||||||||
Sex | male | female | male | male | female | male | male | male | male | male | male | male |
Age (current) | 33 years | 62 years | 9 years | 4 years | 10 years | 8 years | >30 years | 20 years | 16 years | 14 years | 11 years | 15 years |
1st manifestation | infancy | unknown | postnatal | toddler | infancy | infancy | unknown | infancy | infancy | infancy | infancy | infancy |
Intellectual disability | yes | no | yes | yes | yes | no | no | no | yes | yes | yes | yes |
ASD symptoms | yes | no | yes | yes | yes | no | no | no | no | yes | yes | yes |
Neurodevelopmental delay | yes | no | yes | yes | yes | yes | yes | yes | yes | yes | yes | yes |
Obesity | yes | yes | yes | no | no | no | no | yes | yes | yes | Yes | yes |
(BMI [kg/m2]) | (43; 29 years) | (47; 60 years) | (25; 6 years) | (14; 4 years) | (15; 8 years) | ND | ND | (33; 15 years) | (36; 15 years) | (35; 13 years) | (34; 10 years) | (54; 14 years) |
Hyperphagia | yes | yes | yes | no | no | no | no | yes | no | yes | yes | yes |
Diabetes | yes | yes | no | no | no | no | no | no | no | no | no | no |
Morphological CNS anomaly | ND | ND | brain MRI normal | ND | brain MRI normal | leuko-encephalopathy | leuko-encephalopathy | brain MRI normal | brain MRI normal | ND | ND | microcephaly |
Uro-renal anomalies | CAKUT: hydro-nephrosis | no | no | no | no | CAKUT: ureter duplex, dysplastic kidneys | neurogenic bladder | no | no | no | no | no |
The variants reported refer to GenBank: NM_005604.4. Abbreviations: ACMG, American College of Medical Genetics and Genomics; ASD, autism spectrum disorder; CADD, Combined Annotation Dependent Depletion (v1.4); CAKUT, congenital anomalies of the kidney and urinary tract; CNS, central nervous system; het, heterozygous; MAF, minor allele frequency; MRI, magnetic resonance imaging; ND, no data.
Additional variant in COL4A2 (GenBank: NM_001846.3): c.315+1G>C, splice site analysis confirmed pathogenicity by exon skipping.
Additional variant in KDM3B (GenBank: NM_016604.3): c.5191G>A (p.Glu1731Lys).14
According to https://www.uniprot.org/uniprot/P20265; gnomAD v2.1.1 (http://gnomad.broadinstitute.org/).